Lubiprostone Dosing and Efficacy for Chronic Idiopathic Constipation

Dosing Regimen Details

The FDA recommends that lubiprostone should be taken with food and water to reduce the risk of nausea 1, 2
The duration of treatment in clinical trials was 4 weeks, but the FDA drug label does not provide a specific time limit for therapy 1, 2

Patients with moderate to severe hepatic impairment should receive a reduced dose of 8 mcg twice daily 3, 4
No dose adjustment is needed for elderly patients, as efficacy in persons 65 years and older is comparable to the overall population 3

Lubiprostone is a chloride channel activator that works by increasing intestinal fluid secretion and accelerating gastrointestinal transit 1
It acts locally within the intestinal tract with minimal systemic absorption 3
Effects generally manifest within 2 days in patients who respond to treatment 3

Clinical trials demonstrated that lubiprostone resulted in an increased number of spontaneous bowel movements (SBMs) per week compared with placebo (MD 1.98, 95% CI 1.17–2.79) 1
Lubiprostone increases responder rates (RR 1.67, 95% CI 1.36–2.06) 1
Improves stool form and consistency as measured on a 0-4 point scale 1
Also improves abdominal discomfort and bloating, which are bothersome symptoms in some individuals with CIC 3

Nausea is the most common adverse event (reported in up to 35% of individuals), but is typically mild to moderate 3
The risk of nausea is dose-dependent and can be reduced when taken with food and water 1
Only about 5% of patients discontinue therapy due to nausea 3
Patients may be at increased risk of diarrhea leading to discontinuation of treatment compared with placebo 1, 2

Lubiprostone is suggested for adults with CIC who do not respond to over-the-counter (OTC) agents 1, 5
Can be used as a replacement for or as an adjunct to OTC agents 1, 2
For IBS-C, a lower dose of 8 mcg twice daily is recommended, highlighting the importance of using the correct dose for the specific indication 3

In clinical trials, nausea was reported in approximately 35 % of patients receiving lubiprostone, most cases being mild‑to‑moderate; 5 % of patients discontinued therapy because of nausea. This finding is based on randomized controlled trial data. 6
Systemic absorption of lubiprostone is negligible, with the drug being almost completely metabolized within the intestinal lumen; low‑level M3 metabolite can be detected in serum but is not linked to hematologic effects. Evidence derives from pharmacokinetic studies in trial participants. 6

No hematologic abnormalities, including leukocytosis, have been documented in pivotal trials, FDA labeling, or major gastroenterology guidelines, indicating a high level of evidence that lubiprostone does not cause leukocytosis. 6